Corbus Pharmaceuticals (CRBP) News Today

StockNews.com lowered shares of Corbus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at HC Wainwright issued their Q2 2024 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors on Monday, July 22nd. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received an average recommendation of "Buy" from the four analysts that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation. The average

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Up 3.1%

Mirae Asset Global Investments Co. Ltd. bought a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 24,880 shares of the biopharmaceutical com

Corbus Pharmaceuticals (NASDAQ:CRBP) Reaches New 52-Week High at $57.20

Oppenheimer reiterated an "outperform" rating and issued a $80.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday.

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Up 5.3%

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 623,900 shares, an increase of 69.0% from the May 31st total of 369,100 shares. Currently, 6.0% of the shares of the company are short sold. Based on an average trading volume of 244,900 shares, the short-interest ratio is currently 2.5 days.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Investment analysts at B. Riley issued their Q2 2024 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research note issued on Tuesday, June 25th. B. Riley analyst K. Patel forecasts that the biopharmaceutical co

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above Fifty Day Moving Average of $42.66

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) CFO Sean F. Moran sold 1,958 shares of the firm's stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $42.12, for a total transaction of $82,470.96. Following the sale, the chief financial officer now owns 48,605 shares of the company's stock, valued at $2,047,242.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 369,100 shares, a decline of 28.1% from the May 15th total of 513,200 shares. Based on an average trading volume of 251,100 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.5% of the company's stock are sold short.

Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 7.6%

Corbus Pharmaceuticals (NASDAQ:CRBP) Hits New 52-Week High After Analyst Upgrade

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Up 10.6% Following Analyst Upgrade

Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Up 3.2% on Analyst Upgrade

StockNews.com cut Corbus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday.

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Gap Up After Analyst Upgrade

StockNews.com lowered shares of Corbus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday.

Corbus Pharmaceuticals (NASDAQ:CRBP) Reaches New 1-Year High at $50.30

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Up 5.2%

Oppenheimer lifted their price objective on shares of Corbus Pharmaceuticals from $58.00 to $60.00 and gave the company an "outperform" rating in a research note on Wednesday.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 475,600 shares, an increase of 17.8% from the March 15th total of 403,800 shares. Based on an average daily volume of 912,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.6% of the company's stock are short sold.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 403,800 shares, an increase of 560.9% from the February 29th total of 61,100 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average daily volume of 886,400 shares, the days-to-cover ratio is currently 0.5 days.